X4 Pharmaceuticals, Inc.
X4 Pharmaceuticals, Inc. (XFOR) Revenue
Annual & quarterly revenue history · segment & region breakdown
XFOR · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsX4 Pharmaceuticals, Inc. trailing twelve-month (TTM) revenue is $0.01B, an increase of 1273.21% year-over-year from $0.04B in FY2025.
Revenue trend
2025 – 2015 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.04B | +$0.03B | +1273.21% |
| 2024-12-31 | $0.00B | +$0.00B | — |
| 2023-12-31 | $0.00B | +$0.00B | — |
| 2022-12-31 | $0.00B | +$0.00B | — |
| 2021-12-31 | $0.00B | -$0.00B | -100.00% |
| 2020-12-31 | $0.00B | +$0.00B | — |
| 2019-12-31 | $0.00B | +$0.00B | — |
| 2018-12-31 | $0.00B | +$0.00B | — |
| 2017-12-31 | $0.00B | +$0.00B | — |
| 2016-12-31 | $0.00B | +$0.00B | — |
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income X4 Pharmaceuticals, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
X4 Pharmaceuticals, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from X4 Pharmaceuticals, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
XFOR revenue · 4 questionsXFOR's trailing twelve-month (TTM) revenue is $0.01B. That is an increase of 1273.21% year-over-year from $0.04B in FY2025.
▸ Source: FMP · X4 Pharmaceuticals, Inc. SEC filings · GAAP · X4 Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026